@article{ATM32539,
author = {Lejia Sun and Huayu Yang and Yilei Mao},
title = {Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 8},
year = {2019},
keywords = {},
abstract = {Tumor immunotherapy, particularly programmed cell death protein 1 (PD-1)/programmed death ligand-1 (PD-L1) immune checkpoint blockade, has been instrumental in the successful treatment of cancer. Anti-PD-1/PD-L1 immunotherapy has been approved for many types of cancer (1,2); however, it is generally understood that only a fraction of cancer patients benefit from the therapy, which limits the application of immune checkpoint inhibitors (3). Predicting the therapeutic responses to immune checkpoint inhibitors is a focus of many studies.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/32539}
}